secwatch.observer — SEC 8-K summary
======================================

Issuer:     Emergent BioSolutions Inc. (EBS)
CIK:        0001367644
Form:       8-K
Filed at:   2025-03-10T23:59:59+00:00
Accession:  0001367644-25-000054
Event type: m_and_a
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Emergent BioSolutions sells Baltimore-Bayview manufacturing site to Syngene for $36.5M
--------------------------------------------------------------------------------

- Sale of Bayview drug substance manufacturing facility to Syngene Intl for ~$36.5M; closing expected Q1 2025.
- Emergent retains rights to secure manufacturing services and capacity at the facility for growth and pandemic response.
- Emergent continues streamlined manufacturing network with facilities in Lansing, MI and Winnipeg, MB.
- Bayview site received FDA 'No Action Indicated' (NAI) inspection outcome in March 2024.
- CEO Joe Papa states sale advances multi-year transformation plan and turnaround phase.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1367644/000136764425000054/0001367644-25-000054-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1367644/000136764425000054/ebs-20250310.htm
  HTML page:      https://secwatch.observer/filing/0001367644-25-000054

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer